What components should be included in a comprehensive anaphylaxis emergency kit and what are the administration guidelines for each item?

Anaphylaxis Emergency Kit Components and Administration Guidelines

Essential Kit Components

An anaphylaxis emergency kit must include intramuscular epinephrine as the only first-line medication, with all other items serving as adjunctive support. 1

Core Medications

• Epinephrine autoinjectors (two devices required):

  • 0.1 mg for infants >7.5 kg (where available) 1
  • 0.15 mg for patients weighing 10–25 kg 1, 2
  • 0.3 mg for patients weighing ≥25 kg 1, 2
  • Pre-filled syringes of diluted epinephrine (100 μg/mL) for healthcare settings 1

• H1 antihistamines (adjunctive only, never first-line):

  • Diphenhydramine 25–50 mg IV/IM for adults, or 1–2 mg/kg for children 1, 2
  • Oral liquid formulations preferred over tablets for faster absorption 2

• H2 antihistamines (optional adjunct):

  • Ranitidine 50 mg IV or famotidine 20 mg IV 1

• Bronchodilators:

  • Albuterol 2.5–5 mg nebulized solution for persistent bronchospasm 1, 2

• Glucagon (for patients on beta-blockers):

  • 1–5 mg IV over 5 minutes, followed by 5–15 μg/min infusion 1, 2

Equipment and Supplies

• Laminated treatment algorithms focused on epinephrine and fluid administration 1
• Oxygen delivery system capable of 6–8 L/min flow 1, 2
• IV access supplies with isotonic crystalloids (normal saline or lactated Ringer's) 1, 2
• Protocols for alternative vasopressor infusion (norepinephrine, vasopressin, phenylephrine, metaraminol) 1
• Monitoring equipment for continuous cardiac and blood pressure monitoring 1

Documentation Materials

• Written anaphylaxis emergency action plan detailing symptoms, triggers, and clear epinephrine administration instructions 1, 2
• Autoinjector expiration date tracking system 1

---

Administration Guidelines by Component

Epinephrine (First-Line Treatment)

Administer intramuscular epinephrine immediately into the mid-anterolateral thigh (vastus lateralis) as soon as anaphylaxis is recognized—this achieves peak plasma concentrations in 8±2 minutes compared to 34±14 minutes for subcutaneous injection. 1, 2

Dosing:

• Adults and adolescents ≥50 kg: 0.3–0.5 mg of 1:1000 (1 mg/mL) solution IM 1, 2
• Prepubertal children: 0.01 mg/kg IM (maximum 0.3 mg) 1, 2
• Repeat every 5–15 minutes if symptoms persist—approximately 10–20% of patients require more than one dose 1, 2

Critical safety points:

• No absolute contraindications exist, even in elderly patients with cardiovascular disease 1
• Never delay epinephrine while establishing IV access 1
• Never use 1:1000 concentration for IV administration 1

Patient Positioning (Immediate Action)

• Place patient supine with legs elevated to augment venous return (can shift up to 35% of intravascular volume back into circulation) 1, 2
• If respiratory distress or vomiting present, position for comfort 2
• In pregnant women, perform left uterine displacement to avoid aortocaval compression 1
• Never allow patient to stand, walk, or run—sudden postural changes can precipitate fatal cardiovascular collapse 1, 2

Oxygen Therapy (Adjunctive)

• Administer 6–8 L/min supplemental oxygen for any patient with respiratory symptoms or who required multiple epinephrine doses 1, 2

Fluid Resuscitation (Adjunctive)

For Grade II reactions:

• Initial bolus of 0.5 L crystalloids 1

For Grade III reactions:

• Initial bolus of 1 L crystalloids 1
• Adults: 5–10 mL/kg in first 5 minutes (≈1–2 L total), up to 20–30 mL/kg based on response 1, 2
• Children: up to 30 mL/kg within first hour 1, 2

Antihistamines (Second-Line Only)

H1 antihistamines treat only urticaria and itching—they do NOT prevent or reverse cardiovascular collapse or airway obstruction. 1

• Administer only after epinephrine, never before or instead of 1, 2
• Diphenhydramine 25–50 mg IV/IM (adults) or 1–2 mg/kg (children, maximum 50 mg) 1, 2
• May add H2 antihistamine (ranitidine 50 mg IV) with H1 blocker, though evidence of benefit is minimal 1

Bronchodilators (For Persistent Bronchospasm)

• Albuterol 2.5–5 mg nebulized in 3 mL saline after epinephrine administration 1, 2
• Does NOT treat airway edema or cardiovascular collapse 1

Corticosteroids (NOT Recommended for Acute Phase)

Glucocorticoids have a delayed onset of 4–6 hours and do NOT prevent biphasic reactions—they should NOT be relied upon in acute anaphylaxis management. 3, 1

• If administered empirically: methylprednisolone 1–2 mg/kg/day IV every 6 hours or hydrocortisone 200 mg IV 1, 2
• Evidence shows no benefit in preventing biphasic anaphylaxis (OR 0.87; 95% CI 0.74–1.02) 3
• In children, glucocorticoids may actually increase risk of biphasic reactions (OR 1.55; 95% CI 1.01–2.38) 3

---

Refractory Anaphylaxis Management

For patients not responding to initial treatment (≥3 IM epinephrine doses and adequate fluids):

IV Epinephrine (Monitored Setting Only)

• Use only 1:10,000 concentration (0.1 mg/mL) with continuous cardiac monitoring 1
• Grade II reactions: 20 μg IV bolus 1
• Grade III reactions: 50–100 μg IV bolus 1
• Grade IV reactions: 1 mg IV (following advanced life support guidelines) 1
• Continuous infusion: 0.05–0.1 μg/kg/min (≈1–4 μg/min in adults, maximum 10 μg/min) 1, 2

Alternative Vasopressors

• Norepinephrine, vasopressin, phenylephrine, or metaraminol for persistent hypotension 1

Special Considerations for Beta-Blocker Patients

• Glucagon 1–5 mg IV over 5 minutes (20–30 μg/kg in children, maximum 1 mg) 1, 2
• Followed by infusion of 5–15 μg/min 1, 2
• Be aware of possible vomiting as side effect 1

---

Observation and Monitoring Requirements

All patients must be observed in a facility capable of managing anaphylaxis until symptoms have fully resolved, with minimum observation periods based on risk stratification. 3, 1

Standard Observation

• Minimum 4–6 hours after complete symptom resolution for all patients 3, 1, 2

Extended Observation or Admission (≥6 Hours)

Required for patients with any of the following high-risk features:

• Received >1 epinephrine dose (strongest predictor; NNM = 13 to detect one biphasic reaction) 3, 1
• Severe initial presentation (hypotension, respiratory compromise, cardiovascular instability) 3, 1
• Wide pulse pressure at presentation 3, 1
• Unknown anaphylaxis trigger 3, 1
• Drug trigger in children 3, 1
• Cardiovascular comorbidity 3, 1
• Coexisting asthma, especially poorly controlled 3, 1
• Lack of access to epinephrine or emergency services 3, 1
• Poor self-management skills 3, 1

Biphasic anaphylaxis occurs in 1–20% of cases, typically around 8 hours after initial reaction but may appear up to 72 hours later. 3, 1

Tryptase Sampling Protocol

• First sample: 1 hour after reaction onset 1
• Second sample: 2–4 hours after onset 1
• Baseline sample: ≥24 hours post-reaction for comparison 1

---

Critical Pitfalls to Avoid

• Never delay IM epinephrine while establishing IV access—IM injection achieves therapeutic levels faster 1, 2
• Never rely on antihistamines or corticosteroids to treat airway obstruction or cardiovascular collapse 1, 2
• Never discharge solely based on symptom resolution—biphasic reactions can develop many hours later 3, 1
• Never use 1:1000 epinephrine concentration for IV administration—only 1:10,000 is safe 1
• Never administer antihistamines before epinephrine—this delays life-saving first-line treatment 3, 1